Retina Synthesis

Michael Goldstein MD, MM Chief Medical Officer at Ocular Therapeutix also served as Co-Director, Cornea, External Disease and Cataract Service; Refractive Surgery Service; Uveitis & Immunology Service; Assistant Professor, Tufts University School of Medicine.

Spotlight on David Zacks, M.D., Ph. D. Co-Founder and Chief Science Officer at ONL Therapeutics.

Focus on Kourous Rezaei Chief Medical Officer at IVERIC bio in a discussion with Charles Wykoff.

Join Dr. Carmen Puliafito and Adam Rogers, MD in a discussion on Hemera Biosciences's approach in treating Geographic atrophy.

Dr. Philip Rosenfeld of the Bascom Palmer Eye Institute joins Dr. Charles Wykoff and Dr. Carmen Puliafito in a wide ranging discussion on what every clinician needs to know about macular degeneration.

Dr. Philip Rosenfeld of the Bascom Palmer Eye Institute joins Dr. Charles Wykoff and Dr. Carmen Puliafito furthering questions about geographic atrophy and the future of retina imaging.

Join us in a discussion with Jay S. Duker, MD Chief Strategic Scientific Officer of EyePoint Pharmaceuticals. Director of New England Eye Center, Professor and Chair of Ophthalmology at Tufts University School of Medicine with our moderator Dr. Carmen Puliafito.

Thomas Ciulla, vitreoretinal surgeon and current Chief Medical Officer at Clearside Biomedical, discusses his journey through academics, private practice and into the pharmaceutical industry, describing the motivations that have driven his career path choices.

Join us in a discussion with Dr. Karl Csaky CEO of Retina Foundation of the Southwest also Co-Founder of Vinci Pharmaceuticals with our moderator Dr. Carmen Puliafito.

Join Charles C. Wykoff MD, PhD for a conversation with Jason Ehrlich, MD, PhD, Chief Medical Officer, Chief Development Officer at Kodiak Sciences. Jason Ehrlich, ophthalmologist by training discusses insights gleaned along the road of drug development.